지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.3
- 수록면
- 316 - 324 (9page)
이용수
초록· 키워드
오류제보하기
Background: Korea Red Ginseng (KRG) has been used as remedies with hepato-protective effects in liver-related condition. Microbiota related gut-liver axis plays key roles in the pathogenesis of chronic liver disease. We evaluated the effect of KRG on gut-liver axis in patients with nonalcoholic statohepatitis by the modulation of gut-microbiota.
Methods: A total of 94 patients (KRG: 45 and placebo: 49) were prospectively randomized to receive KRG (2,000 ㎎/day, ginsenoside Rg1þRb1þRg3 4.5㎎/g) or placebo during 30 days. Liver function test, cytokeraton 18, and fatigue score were measured. Gut microbiota was analyzed by MiSeq systems based on 16S rRNA genes.
Results: In KRG group, the mean levels (before vs. after) of aspartate aminotransferase (53 ± 19 vs. 45 ± 23 IU/L), alanine aminotransferase (75 ± 40 vs. 64 ± 39 IU/L) and fatigue score (33 ± 13 vs. 26 ± 13) were improved (p ＜ 0.05). In placebo group, only fatigue score (34 ± 13 vs. 31 ± 15) was ameliorated (p ＜ 0.05). The changes of phyla were not statistically significant on both groups. In KRG group, increased abundance of Lactobacillus was related with improved alanine aminotransferase level and increased abundance of Clostridium and Intestinibacter was associated with no improvement after KRG supplementation. In placebo group, increased abundance of Lachnospiraceae could be related with aggravation of liver enzyme (p ＜ 0.05).
Conclusion: KRG effectively improved liver enzymes and fatigue score by modulating gut-microbiota in patients with fatty liver disease. Further studies are needed to understand the mechanism of improvement of nonalcoholic steatohepatitis.
Methods: A total of 94 patients (KRG: 45 and placebo: 49) were prospectively randomized to receive KRG (2,000 ㎎/day, ginsenoside Rg1þRb1þRg3 4.5㎎/g) or placebo during 30 days. Liver function test, cytokeraton 18, and fatigue score were measured. Gut microbiota was analyzed by MiSeq systems based on 16S rRNA genes.
Results: In KRG group, the mean levels (before vs. after) of aspartate aminotransferase (53 ± 19 vs. 45 ± 23 IU/L), alanine aminotransferase (75 ± 40 vs. 64 ± 39 IU/L) and fatigue score (33 ± 13 vs. 26 ± 13) were improved (p ＜ 0.05). In placebo group, only fatigue score (34 ± 13 vs. 31 ± 15) was ameliorated (p ＜ 0.05). The changes of phyla were not statistically significant on both groups. In KRG group, increased abundance of Lactobacillus was related with improved alanine aminotransferase level and increased abundance of Clostridium and Intestinibacter was associated with no improvement after KRG supplementation. In placebo group, increased abundance of Lachnospiraceae could be related with aggravation of liver enzyme (p ＜ 0.05).
Conclusion: KRG effectively improved liver enzymes and fatigue score by modulating gut-microbiota in patients with fatty liver disease. Further studies are needed to understand the mechanism of improvement of nonalcoholic steatohepatitis.
목차
ABSTRACT
1. Introduction
2. Materials and methods
3. Results
4. Discussion
References
참고문헌 (47)
참고문헌 신청
Kleiner DE / 2005 / Design and validation of a histological scoring system for nonalcoholic fatty liver disease / Hepatology 41:1313~1321
Brunt EM / 2012 / Nonalcoholic fatty liver disease : what the pathologist can tell the clinician / Digest Dis 30:61~68
Morris G / 2015 / Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses / BMC Med 13:28
Schuppan D / 2013 / Non-alcoholic steatohepatitis : pathogenesis and novel therapeutic approaches / J Gastroenterol Hepatol 28:68~76
Brunt EM / 2015 / Nonalcoholic fatty liver disease / Nat Rev Dis Primers 1:15080
Brunt EM / 2012 / Nonalcoholic fatty liver disease : what the pathologist can tell the clinician / Digest Dis 30:61~68
Morris G / 2015 / Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses / BMC Med 13:28
Schuppan D / 2013 / Non-alcoholic steatohepatitis : pathogenesis and novel therapeutic approaches / J Gastroenterol Hepatol 28:68~76
Brunt EM / 2015 / Nonalcoholic fatty liver disease / Nat Rev Dis Primers 1:15080
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Gut-Liver Axis in Liver Disease
대한외과학회 학술대회 초록집
2019 .10
-
Effect of Korean Red Ginseng in chronic liver disease
Journal of Ginseng Research
2017 .10
-
Korean Red Ginseng alleviates dextran sodium sulfate-induced colitis through gut microbiota modulation in mice
Journal of Ginseng Research
2024 .11
-
Liver
대한외과학회 학술대회 초록집
2016 .11
-
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Clinical and Molecular Hepatology
2023 .02
-
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Clinical and Molecular Hepatology
2023 .04
-
Personalized medicine in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .10
-
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
Journal of Obesity & Metabolic Syndrome
2020 .01
-
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
Gut and Liver
2024 .07
-
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .07
-
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Clinical and Molecular Hepatology
2023 .04
-
Effect of Lactobacillus dominance modified by Korean Red Ginseng on the improvement of Alzheimer"s disease in mice
Journal of Ginseng Research
2022 .05
-
The effects of Korean Red Ginseng on stress-related neurotransmitters and gene expression: A randomized, double-blind, placebo-controlled trial
Journal of Ginseng Research
2023 .11
-
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Diabetes and Metabolism Journal
2022 .07
-
Implications of comorbidities in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study
Clinical Hypertension
2015 .01
-
The growing burden of non-alcoholic fatty liver disease on mortality
Clinical and Molecular Hepatology
2023 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0